<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">79946</article-id><article-id pub-id-type="doi">10.7554/eLife.79946</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open label interventional study</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-234072"><name><surname>Ehrlich</surname><given-names>Avner</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6339-1665</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-234073"><name><surname>Ioannidis</surname><given-names>Konstantinos</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288934"><name><surname>Nasar</surname><given-names>Makram</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288935"><name><surname>Abu Alkian</surname><given-names>Ismaeel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-301107"><name><surname>Daskal</surname><given-names>Yuval</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288936"><name><surname>Atari</surname><given-names>Nofar</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288937"><name><surname>Kliker</surname><given-names>Limor</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288938"><name><surname>Rainy</surname><given-names>Nir</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288939"><name><surname>Hofree</surname><given-names>Matan</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288940"><name><surname>Shafran Tikva</surname><given-names>Sigal</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288941"><name><surname>Houri</surname><given-names>Inbal</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288942"><name><surname>Cicero</surname><given-names>Arrigo</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-288943"><name><surname>Pavanello</surname><given-names>Chiara</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5892-9857</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288944"><name><surname>Sirtori</surname><given-names>Cesare R</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-288945"><name><surname>Cohen</surname><given-names>Jordana B</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-288946"><name><surname>Chirinos</surname><given-names>Julio A.</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-288947"><name><surname>Deutsch</surname><given-names>Lisa</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2445-7561</contrib-id><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-288949"><name><surname>Cohen</surname><given-names>Merav</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288950"><name><surname>Gottlieb</surname><given-names>Amichai</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288953"><name><surname>Bar-Chaim</surname><given-names>Adina</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288952"><name><surname>Shibolet</surname><given-names>Oren</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-60238"><name><surname>Mandelboim</surname><given-names>Michal</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250109"><name><surname>Maayan</surname><given-names>Shlomo</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-111438"><name><surname>Nahmias</surname><given-names>Yaakov</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6051-616X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf9"/></contrib><aff id="aff1"><institution content-type="dept">Grass Center for Bioengineering</institution>, <institution>Hebrew University of Jerusalem</institution>, <addr-line><named-content content-type="city">Jerusalem</named-content></addr-line>, <country>Israel</country></aff><aff id="aff2"><institution content-type="dept">Division of Infectious Diseases</institution>, <institution>Barzilai Medical Center</institution>, <addr-line><named-content content-type="city">Ashkelon</named-content></addr-line>, <country>Israel</country></aff><aff id="aff3"><institution content-type="dept">Central Virology Laboratory</institution>, <institution>Sheba Medical Center</institution>, <addr-line><named-content content-type="city">Tel Hashomer</named-content></addr-line>, <country>Israel</country></aff><aff id="aff4"><institution content-type="dept">Laboratory Division</institution>, <institution>Shamir (Assaf Harofeh) Medical Center</institution>, <addr-line><named-content content-type="city">Zerifin</named-content></addr-line>, <country>Israel</country></aff><aff id="aff5"><institution content-type="dept">Klarman Cell Observatory</institution>, <institution>Broad Institute</institution>, <addr-line><named-content content-type="city">Cambridge,</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Department of Nursing</institution>, <institution>Jerusalem College of Technology</institution>, <addr-line><named-content content-type="city">Jerusalem</named-content></addr-line>, <country>Israel</country></aff><aff id="aff7"><institution content-type="dept">Department of Gastroenterology</institution>, <institution>Tel Aviv Sourasky Medical Center</institution>, <addr-line><named-content content-type="city">Tel Aviv</named-content></addr-line>, <country>Israel</country></aff><aff id="aff8"><institution>Policlinico S.Orsola-Malpighi</institution>, <addr-line><named-content content-type="city">Bologna</named-content></addr-line>, <country>Italy</country></aff><aff id="aff9"><institution content-type="dept">Dipartimento di Scienze Farmacologiche e Biomolecolari</institution>, <institution>Università degli Studi di Milano</institution>, <addr-line><named-content content-type="city">Milano</named-content></addr-line>, <country>Italy</country></aff><aff id="aff10"><institution content-type="dept">Centro Dislipidemie</institution>, <institution>Niguarda Hospital</institution>, <addr-line><named-content content-type="city">Milano</named-content></addr-line>, <country>Italy</country></aff><aff id="aff11"><institution content-type="dept">Perelman School of Medicine</institution>, <institution>University of Pennsylvania</institution>, <addr-line><named-content content-type="city">Philadelphia</named-content></addr-line>, <country>United States</country></aff><aff id="aff12"><institution>BioStats Statistical Consulting Ltd</institution>, <addr-line><named-content content-type="city">Modiin</named-content></addr-line>, <country>Israel</country></aff><aff id="aff13"><institution content-type="dept">Central Virology Laboratory</institution>, <institution>Sheba Medical Center</institution>, <addr-line><named-content content-type="city">Ramat-Gan</named-content></addr-line>, <country>Israel</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1067"><name><surname>Czech</surname><given-names>Michael</given-names></name><role>Reviewing editor</role><aff><institution>University of Massachusetts Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>ynahmias@gmail.com</email> (YN);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>27</day><month>01</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e79946</elocation-id><history><date date-type="received"><day>03</day><month>05</month><year>2022</year></date><date date-type="accepted"><day>26</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Ehrlich et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Ehrlich et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-79946-v1.pdf"/><abstract><p><bold>Background:</bold> Viral infection is associated with a significant rewire of the host metabolic pathways, presenting attractive metabolic targets for intervention.</p><p><bold>Methods:</bold> We chart the metabolic response of lung epithelial cells to SARS-CoV-2 infection in primary cultures and COVID-19 patient samples and perform <italic>in vitro</italic> metabolism-focused drug screen on primary lung epithelial cells infected with different strains of the virus. We perform observational analysis of Israeli patients hospitalized due to COVID-19 and comparative epidemiological analysis from cohorts in Italy and the Veteran's Health Administration in the United States. In addition, we perform a prospective non-randomized interventional open-label study in which 15 patients hospitalized with severe COVID-19 were given 145 mg/day of nanocrystallized fenofibrate added to the standard of care.</p><p><bold>Results:</bold> SARS-CoV-2 infection produced transcriptional changes associated with increased glycolysis and lipid accumulation. Metabolism-focused drug screen showed that fenofibrate reversed lipid accumulation and blocked SARS-CoV-2 replication through a PPARa-dependent mechanism in both alpha and delta variants. Analysis of 3,233 Israeli patients hospitalized due to COVID-19 supported <italic>in vitro</italic> findings. Patients taking fibrates showed significantly lower markers of immunoinflammation and faster recovery. Additional corroboration was received by comparative epidemiological analysis from cohorts in Europe and the United States. A subsequent prospective non-randomized interventional open-label study was carried out on 15 patients hospitalized with severe COVID-19. The patients were treated with 145 mg/day of nanocrystallized fenofibrate in addition to standard-of-care. Patients receiving fenofibrate demonstrated a rapid reduction in inflammation and a significantly faster recovery compared to patients admitted during the same period.</p><p><bold>Conclusions:</bold> Taken together, our data suggest that pharmacological modulation of PPARa should be strongly considered as a potential therapeutic approach for SARS-CoV-2 infection and emphasizes the need to complete the study of fenofibrate in large randomized controlled clinical trials.</p><p><bold>Funding:</bold> Funding was provided by European Research Council Consolidator Grants OCLD (project no. 681870) and generous gifts from the Nikoh Foundation and the Sam and Rina Frankel Foundation (YN). The interventional study was supported by Abbott (project FENOC0003).</p><p><bold>Clinical trial number:</bold> NCT04661930.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>681870</award-id><principal-award-recipient><name><surname>Nahmias</surname><given-names>Yaakov</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Nikoh Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Nahmias</surname><given-names>Yaakov</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Sam and Rina Frankel</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Nahmias</surname><given-names>Yaakov</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Abbott</institution></institution-wrap></funding-source><award-id>FENOC0003</award-id><principal-award-recipient><name><surname>Nahmias</surname><given-names>Yaakov</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Avner Ehrlich, is registered as an investor in a PCT regarding the use of metabolic regulators for COVID. The author has a patent on the use of PPAR agonists to treat COVID. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf3"><p>Arrigo Cicero, has received personal honoraria for statistical consultation from Recipharm, and personal honoraria for manuscript writing from both Sharper Srl and Fidia Pharmaceuticals. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf4"><p>Cesare R Sirtori, is President of Fondazione (totally supported by family). The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf5"><p>Jordana B Cohen, received funding from National Institutes of Health (1R01HL157108-01A1,1R01AG074989-01) . The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf6"><p>Julio A. Chirinos, has received consulting honoraria from Sanifit, Bristol Myers Squibb, Merck, Edwards Lifesciences, Bayer, JNJ, Fukuda-Denshi, NGM Bio, Mayo institute of technology and the University of Delaware, and research grants from the National Institutes of Health, Abbott, Microsoft, Fukuda-Denshi and Bristol Myers Squibb. He has received compensation from the American Heart Association and the American College of Cardiology for editorial roles, and visiting speaker honoraria from Washington University, Emory University, University of Utah, the Japanese Association for Cardiovascular Nursing and the Korean Society of Cardiology. The author is named as inventor in a University of Pennsylvania patent for the use of inorganic nitrates/nitrites for the treatment of Heart Failure and Preserved Ejection Fraction and for the use of biomarkers in heart failure with preserved ejection fraction. The author has participated on the Advisory board for Bristol-Myers Squibb Data safety monitoring board for studies by the University of Delaware and UT Southwestern, and is Vice President of North American Artery Society. The author has received research device loans from Atcor Medical, Fukuda-Denshi, Unex, Uscom, NDD Medical Technologies, Microsoft, and MicroVision Medical. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf7"><p>Lisa Deutsch, is affiliated with BioStats Statistical Consulting Ltd where they work as a Biostatistician. The authors has received payment for statistical work for the manuscript and consulting fees from Tissue Dynamics Ltd. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf8"><p>Oren Shibolet, has received consulting honoraria from Sanofi, Roche and Neopharm, and lectures honoraria from Roche . He is the chairmen of the Israel Association for the study of the liver. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf9"><p>Yaakov Nahmias, is registered as an investor in a PCT regarding the use of metabolic regulators for COVID and has a patent on the use of PPAR agonists to treat COVID. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.In the observational studies - the Israeli study was approved by the local institutional review board of the Hadassah Medical Center (IRB approval number no. HMO 0247-20) and the local institutional review board of the Ichilov Medical Center (IRB approval number no. 0282-20-TLV). The Italian study was reviewed by the local ethical board (AVEC) of the IRCSS S.Orsola-Malpighi University Hospital (approval number no. code LLD-RP2018).The American study was reviewed by the local institutional review board of the Corporal Michael J. Crescenz VA Medical Center (IRB approval number 01654).The interventional study was conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonisation E6 and the principles of the Declaration of Helsinki or local regulations, whichever afforded greater patient protection. The study was reviewed and approved by the Barzilai Medical Center Research Ethics Committee (0105-20-BRZ).Statistical analysis of the Israeli studies was done by BioStats Statistical Consulting Ltd. (Maccabim, Israel), funded by the sponsor. Data management is performed in compliance with GCP and 21 CFR part 1. Statistical analyses and reporting are performed in compliance with E6 GCP, E9, and ISO 14155. Independently validated by the author. Statistical analysis of the Italian study was done by Prof. Arrigo Cicero and Dr. Chiara Pavanello. Statistical analysis of the US study was done by Prof. Jordana Cohen.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Software resources: Our custom Cell Analysis CellProfiler® Pipeline is available on https://github.com/avnere/Single-Cell-Analysis-CellProfiler-Pipeline.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>tenOever BR</collab><collab>Blanco-Melo D</collab></person-group><year iso-8601-date="2020">2020</year><source>Transcriptional response to SARS-CoV-2 infection</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147507">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147507</ext-link><comment>NCBI Gene Expression Omnibus, GSE147507</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Liao M</collab><collab>Liu Y</collab><collab>Yuan J</collab><collab>Wen Y</collab><collab>Xu G</collab><collab>Zhao J</collab><collab>Cheng L</collab><collab>Li J</collab><collab>Wang X</collab><collab>Wang F</collab><collab>Liu L</collab><collab>Amit I</collab><collab>Zhang S</collab><collab>Zhang Z</collab></person-group><year iso-8601-date="2020">2020</year><source>Single-cell landscape of bronchoalveolar immune cells in COVID-19 patients</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145926">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145926</ext-link><comment>NCBI Gene Expression Omnibus, GSE145926</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Vanderheiden A</collab><collab>Ralfs P</collab><collab>Chirkova T</collab><collab>Upadhyay A</collab><collab>Zimmerman M</collab><collab>Danzy S</collab><collab>Pellegrini K</collab><collab>Manfredi C</collab><collab>Sorscher E</collab><collab>Mainou B</collab><collab>Lobby J</collab><collab>Kohlmeier J</collab><collab>Lowen A</collab><collab>Shi P</collab><collab>Menachery V</collab><collab>Anderson L</collab><collab>Grakoui A</collab><collab>Bosinger S</collab><collab>Suthar MS</collab></person-group><year iso-8601-date="2020">2020</year><source>Primary Human Airway Epithelial Cultures infected with SARS-CoV-2</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153970">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153970</ext-link><comment>NCBI Gene Expression Omnibus, GSE147507</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-79946-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>